Application of FDG-PET/CT in radiation oncology

Frontiers in Oncology

Volumn 3 APR, Issue , 2013, Pages

  Li, Jun ^a   Xiao, Ying ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

PET CT; Radiation oncology; Radiation therapy; Treatment planning; Treatment response

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FLUOROURACIL;

CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SPECIFIC SURVIVAL; HEAD AND NECK CARCINOMA; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MEDIASTINUM LYMPH NODE; NEOPLASM; OSTEOSARCOMA; OVERALL SURVIVAL; PELVIS LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROSTATE CANCER; RADIATION DOSE; RADIOLOGICAL PARAMETERS; RECTUM CANCER; RECURRENT DISEASE; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; STANDARDIZED UPTAKE VALUE; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA;

EID: 84890584919     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00080     Document Type: Short Survey

References (61)

1. Bettinardi, V., Picchio, M., Di Muzio, N., and Gilardi, M. C. (2012). Motion management in positron emission tomography/computed tomography for radiation treatment planning. Semin. Nucl. Med. 42, 289-307.
2. Borst, G. R., Belderbos, J. S., Boellaard, R., Comans, E. F., De Jaeger, K., Lammertsma, A. A., et al. (2005). Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur. J. Cancer 41, 1533-1541.
3. Bradley, J. D., Perez, C. A., Dehdashti, F., and Siegel, B. A. (2004). Implementing biologic target volumes in radiation treatment planning for non-small cell lung cancer. J. Nucl. Med. 45(Suppl. 1), 96S-101S.
4. Bussink, J., Kaanders, J. H., van der Graaf, W. T., and Oyen, W. J. (2011). PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. Nat. Rev. Clin. Oncol. 8, 233-242.
5. Caldarella, C., Salsano, M., Isgrò, M. A., and Treglia, G. (2012). The role of fluorine-18-fluorodeoxyglucose positron emission tomography in assessing the response to neoadjuvant treatment in patients with osteosarcoma. Int. J. Mol. Imaging 2012, 870301.
6. Cheebsumon, P., Boellaard, R., de Ruysscher, D., van Elmpt, W., van Baardwijk, A., Yaqub, M., et al. (2012). Assessment of tumour size in PET/CT lung cancer studies: PET-and CT-based methods compared to pathology. EJNMMI Res. 2, 56.
7. Choi, N. C., Fischman, A. J., Niemierko, A., Ryu, J. S., Lynch, T., Wain, J., et al. (2002). Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 54, 1024-1035.
8. De Jong, I. J., De Haan, T. D., Wiegman, E. M., Van Den Bergh, A. C., Pruim, J., and Breeuwsma, A. J. (2010). PET/CT and radiotherapy in prostate cancer. Q. J. Nucl. Med. Mol. Imaging 54, 543-552.
9. De Ruysscher, D., Wanders, S., Minken, A., Lumens, A., Schiffelers, J., Stultiens, C., et al. (2005). Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: a planning study. Radiother. Oncol. 77, 5-10.
10. Dolezelova, H., Slampa, P., Ondrova, B., Gombosova, J., Sovadinova, S., Novotny, T., et al. (2008). The impact of PET with 18FDG in radiotherapy treatment planning and in the prediction in patients with cervix carcinoma. Results of pilot study. Neoplasma 55, 437-441.
11. Erdi, Y. E., Rosenzweig, K., Erdi, A. K., MacApinlac, H. A., Hu, Y. C., Braban, L. E., et al. (2002). Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother. Oncol. 62, 51-60.
12. Eschmann, S. M., Friedel, G., Paulsen, F., Reimold, M., Hehr, T., Budach, W., et al. (2006). Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? Eur. J. Nucl. Med. Mol. Imaging 33, 263-269.
13. Facey, K., Bradbury, I., Laking, G., and Payne, E. (2007). Overview of the clinical effectiveness of positron emission tomography in selected cancers. Health Technol. Assess. 11, 3-4.
14. Gagel, B., Reinartz, P., Demirel, C., Kaiser, H. J., Zimny, M., Piroth, M., et al. (2006). [18F] Fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer 6:51. doi:10.1186/1471-2407-6-51
15. Garg, M. K., Glanzman, J., and Kalnicki, S. (2012). The evolving role of positron emission tomography-computed tomography in organ-preserving treatment of head and neck cancer. Semin. Nucl. Med. 42, 320-327.
16. Greco, C., Rosenzweig, K., Cascini, G. L., and Tamburrini, O. (2007). Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC). Lung Cancer 57, 125-134.
17. Gregoire, V., Haustermans, K., Geets, X., Roels, S., and Lonneux, M. (2007). PET-based treatment planning in radiotherapy: a new standard? J. Nucl. Med. 48, 68S-77S.
18. Grigsby, P. W., Siegel, B. A., Dehdashti, F., Rader, J., and Zoberi, I. (2004). Post-therapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J. Clin. Oncol. 22, 2167-2171.
19. Henriques de Figueiredo, B., Barret, O., Demeaux, H., Lagarde, P., De-Mones-Del-Pujol, E., Kantor, G., et al. (2009). Comparison between CT-and FDG-PET defined target volumes for radiotherapy planning in head and neck cancers. Radiother. Oncol. 93, 479-482.
20. Hicks, R. J. (2005). The role of PET in monitoring therapy. Cancer Imaging 5, 51-57.
21. Hicks, R. J., Mac Manus, M. P., Matthews, J. P., Hogg, A., Binns, D., Rischin, D., et al. (2004). Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int. J. Radiat. Oncol. Biol. Phys. 60, 412-418.
22. Histed, S. N., Lindenberg, M. L., Mena, E., Turkbey, B., Choyke, P. L., and Kurdziel, K. A. (2012). Review of functional/anatomical imaging in oncology. Nucl. Med. Commun. 33, 349-361.
23. Huh, J. W., Min, J. J., Lee, J. H., Kim, H. R., and Kim, Y. J. (2012). The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation. Am. J. Clin. Oncol. 35, 340-344.
24. Janssen, M. H., Öllers, M. C., van Stiphout, R. G., Riedl, R. G., van den Bogaard, J., Buijsen, J., et al. (2012). PET-based treatment response evaluation in rectal cancer: prediction and validation. Int. J. Radiat. Oncol. Biol. Phys. 82, 871-876.
25. Jarritt, P. H., Carson, K. J., Hounsell, A. R., and Visvikis, D. (2006). The role of PET/CT scanning in radiotherapy planning. Br. J. Radiol. 79, S27-S35.
26. Jeong, H. J., Min, J. J., Park, J. M., Chung, J. K., Kim, B. T., Jeong, J. M., et al. (2002). Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl. Med. Commun. 23, 865-870.
27. Juweid, M. E., and Cheson, B. D. (2006). Positron-emission tomography and assessment of cancer therapy. N. Engl. J. Med. 354, 496-507.
28. Kalff, V., Duong, C., Drummond, E. G., Hicks, J. P., and Matthews, R. J. (2006). Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J. Nucl. Med. 47, 14-22.
29. Kidd, E. A., Siegel, B. A., Dehdashti, F., and Grigsby, P. W. (2010). Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer. Cancer 116, 1469-1475.
30. Kovalchuk, N., Jalisi, S., Subramaniam, R. M., and Truong, M. T. (2012). Deformable registration of preoperative PET/CT with postoperative radiation therapy planning CT in head and neck cancer. Radiographics 32, 1329-1341. doi:10.3389/fonc.2012.00071
31. Lavrenkov, K., Partridge, M., Cook, G., and Brada, M. (2005). Positron emission tomography for target volume definition in the treatment of non-small cell lung cancer. Radiother. Oncol. 77, 1-4.
32. Lee, J. A. (2010). Segmentation of positron emission tomography images: some recommendations for target delineation in radiation oncology. Radiother. Oncol. 96, 302-307.
33. Lee, J. E., Huh, S. J., Nam, H., and Ju, S. G. (2013). Early response of patients undergoing concurrent chemoradiotherapy for cervical cancer: a comparison of PET/CT and MRI. Ann. Nucl. Med. 27, 37-45.
34. Lee, P., Kupelian, P., Czernin, J., and Ghosh, P. (2012). Current concepts in F18 FDG PET/CT-based radiation therapy planning for lung cancer. Front. Oncol. 2:71.
35. Lin, L. L., Mutic, S., Low, D. A., LaForest, R., Vicic, M., Zoberi, I., et al. (2007). Adaptive brachytherapy treatment planning for cervical cancer using FDG-PET. Int. J. Radiat. Oncol. Biol. Phys. 67, 91-96.
36. Ling, C. C., Humm, J., Larson, S., Amols, H., Fuks, Z., Leibel, S., et al. (2000). Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int. J. Radiat. Oncol. Biol. Phys. 47, 551-560.
37. MacManus, M., Nestle, U., Rosenzweig, K. E., Carrio, I., Messa, C., Belohlavek, O., et al. (2009). Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother. Oncol. 91, 85-94.
38. Nehmeh, S. A., Erdi, Y. E., Meirelles, G. S., Squire, O., Larson, S. M., and Schöder, H. (2007). Deep-inspiration breath-hold PET/CT of the thorax. J. Nucl. Med. 48, 22-26.
39. Nehmeh, S. A., Erdi, Y. E., Pan, T., Pevsner, A., Rosenzweig, K. E., Yorke, E., et al. (2004). Four-dimensional (4D) PET/CT imaging of the thorax. Med. Phys. 31, 3179-3186.
40. Nestle, U., Kremp, S., and Grosu, A. L. (2006). Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother. Oncol. 81, 209-225.
41. Nestle, U., Kremp, S., Schaefer-Schuler, A., Sebastian-Welsch, C., Hellwig, D., Rube, C., et al. (2005). Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J. Nucl. Med. 46, 1342-1348.
42. Paulino, A. C., Koshy, M., Howell, R., Schuster, D., and Davis, L. W. (2005). Comparison of CT-and FDGPET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 61, 1385-1392.
43. Perez, R. O., Habr-Gama, A., Gama-Rodrigues, J., Proscurshim, I., Julião, G. P., Lynn, P., et al. (2012). Accuracy of positron emission tomography/computed tomography and clinical assessment in the detection of complete rectal tumor regression after neoadjuvant chemoradiation: long-term results of a prospective trial (National Clinical Trial 00254683). Cancer 118, 3501-3511.
44. Petit, S. F., Aerts, H. J., van Loon, J. G., Offermann, C., Houben, R., Winkens, B., et al. (2009). Metabolic control probability in tumour subvolumes or how to guide tumour dose redistribution in non-small cell lung cancer (NSCLC): an exploratory clinical study. Radiother. Oncol. 91, 393-398.
45. Pinkawa, M., Piroth, M. D., Holy, R., Klotz, J., Djukic, V., Corral, N. E., et al. (2012). Dose-escalation using intensity-modulated radiotherapy for prostate cancer-evaluation of quality of life with and without (18)F-choline PET-CT detected simultaneous integrated boost. Radiat. Oncol. 7, 14.
46. Porceddu, S. V., Pryor, D. I., Burmeister, E., Burmeister, B. H., Poulsen, M. G., Foote, M. C., et al. (2011). Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. Head Neck 33, 1675-1682.
47. Pöttgen, C., Levegrün, S., Theegarten, D., Marnitz, S., Grehl, S., Pink, R., et al. (2006). Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin. Cancer Res. 12, 97-106.
48. Rege, S., Safa, A. A., Chaiken, L., Hoh, C., Juillard, G., and Withers, H. R. (2000). Positron emission tomography: an independent indicator of radiocurability in head and neck carcinomas. Am. J. Clin. Oncol. 23, 164-169.
49. Rodríguez Fernández, A., Gómez Río, M., Llamas Elvira, J. M., Sánchez-Palencia Ramos, A., Bellón Guardia, M., Ramos Font, C., et al. (2007). Diagnosis efficacy of structural (CT) and functional (FDG-PET) imaging methods in the thoracic and extrathoracic staging of non-small cell lung cancer. Clin. Transl. Oncol. 9, 32-39.
50. Scripes, P. G., and Yaparpalvi, R. (2012). Technical aspects of positron emission tomography/computed tomography in radiotherapy treatment planning. Semin. Nucl. Med. 42, 283-288.
51. Sveistrup, J., Loft, A., Berthelsen, A. K., Henriksen, B. M., Nielsen, M. B., and Engelholm, S. A. (2012). Positron emission tomography/computed tomography in the staging and treatment of anal cancer. Int. J. Radiat. Oncol. Biol. Phys. 83, 134-141.
52. Tejwani, A., Lavaf, A., Parikh, K., Mokhtar, B., Swamy, U., Emmolo, J., et al. (2012). The role of PET/CT in decreasing inter-observer variability in treatment planning and evaluation of response for cervical cancer. Am. J. Nucl. Med. Mol. Imaging 2, 307-313.
53. Terezakis, S. A., Hunt, M. A., Kowalski, A., McCann, P., Schmidtlein, C. R., Reiner, A., et al. (2011). [18F]FDG-Positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematological malignancies. Int. J. Radiat. Oncol. Biol. Phys. 81, 615-622.
54. Toloza, E. M., Harpole, L., and McCrory, D. C. (2003). Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 123(Suppl. 1), 137S-146S.
55. Vaidya, M., Creach, K. M., Frye, J., Dehdashti, F., Bradley, J. D., and El Naqa, I. (2012). Combined PET/CT image characteristics for radiotherapy tumor response in lung cancer. Radiother. Oncol. 102, 239-245.
56. van Baardwijk, A., Bosmans, G., Boersma, L., Buijsen, J., Wanders, S., Hochstenbag, M., et al. (2007). PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int. J. Radiat. Oncol. Biol. Phys. 68, 771-778.
57. van Loon, J., Offermann, C., Ollers, M., van Elmpt, W., Vegt, E., Rahmy, A., et al. (2011). Early CT and FDG-metabolic tumour volume changes show a significant correlation with survival in stage I-III small cell lung cancer: a hypothesis generating study. Radiother. Oncol. 99, 72-75.
58. van Stiphout, R. G., Lammering, G., Buijsen, J., Janssen, M. H., Gambacorta, M. A., Slagmolen, P., et al. (2011). Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging. Radiother. Oncol. 98, 126-133.
59. Yeoh, K. W., and Mikhaeel, N. G. (2013). Are we ready for positron emission tomography/computed tomography-based target volume definition in lymphoma radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 85, 14-20.
60. Yi, C. A., Shin, K. M., Lee, K. S., Kim, B. T., Kim, H., Kwon, O. J., et al. (2008). Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology 248, 632-642.
61. Yu, H. M., Liu, Y. F., Hou, M., Liu, J., Li, X. N., and Yu, J. M. (2009). Evaluation of gross tumor size using CT, 18F-FDG PET, integrated 18F-FDG PET/CT and pathological analysis in non-small cell lung cancer. Eur. J. Radiol. 72, 104-113.